Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.64 |
| ▸ | WDR5 | P61964 | 2/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202790 | 0.83 | ALDH1A1 (0.62) | MYCWDR5ADORA1ADORA2AALDH1A1 | |
| SCHEMBL19638187 | 0.83 | ADORA1 (0.57) | MYCWDR5ADORA1ADORA2ANPSR1 | |
| SCHEMBL30309328 | 0.83 | ADORA1 (0.57) | MYCWDR5ADORA1ADORA2ANPSR1 | |
| SCHEMBL19638111 | 0.81 | SCN5A (0.46) | MYCWDR5ADORA1ADORA2ASMN1; SMN2 | |
| SCHEMBL19637978 | 0.81 | ADORA1 (0.51) | MYCWDR5ADORA1ADORA2AALDH1A1 | |
| SCHEMBL19638228 | 0.81 | MYC (0.44) | MYCWDR5ALDH1A1NPSR1MAPT | |
| SCHEMBL19637944 | 0.80 | PIK3CA (0.52) | MYCWDR5 | |
| SCHEMBL28724215 | 0.80 | MYC (0.61) | MYCWDR5ADORA1ADORA2AALDH1A1 | |
| SCHEMBL1852196 | 0.80 | MYC (0.61) | MYCWDR5ADORA1ADORA2AALDH1A1 | |
| SCHEMBL19650376 | 0.79 | MYC (0.60) | MYCWDR5ADORA1ADORA2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110198939-B | Modulators of adenosine A3 receptors | 帕罗生物制药有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-107207445-B | Adenosine A3Modulators of receptors | 帕罗生物制药有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3581572-B1 | ADENOSINE A3 RECEPTOR MODULATORS | PALOBIOFARMA SL (ES) | 2020-11-25 | — | — | EP | disclosed |
| US-10744125-B2 | Adenosine A3 receptor modulators | PALOBIOFARMA, S.L. (ES) | 2020-08-18 | — | — | US | disclosed |
| CN-110198939-A | The regulator of adenosine A 3 receptor | 帕罗生物制药有限公司 | 2019-09-03 | — | — | CN | disclosed |
| EP-3248964-B1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA SL (ES) | 2019-07-17 | — | — | EP | disclosed |
| EP-3248964-B1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA SL (ES) | 2019-07-17 | — | — | EP | disclosed |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-03-26 | — | — | US | disclosed |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-03-26 | — | — | US | disclosed |
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2018-09-20 | — | — | US | disclosed |
| EP-3248964-A1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA S.L. (ES) | 2017-11-29 | — | — | EP | disclosed |
| EP-3248964-A1 | THIAZOLE MODULATORS OF A3 ADENOSINE RECEPTORS | PALOBIOFARMA S.L. (ES) | 2017-11-29 | — | — | EP | disclosed |
| WO-2016116652-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2016-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263963-A1 | MODULATORS OF THE ADENOSINE A3 RECEPTORS | ADORA3, ADORA2A, ADORA1 | MYC 4788/4885WDR5 3585/4885ADORA1 3/4885 |
| US-10744125-B2 | Adenosine A3 receptor modulators | ADORA3, ADORA2A, ADORA1 | MYC 4695/4885WDR5 3622/4885ADORA1 3/4885 |
| US-10238637-B2 | Modulators of the adenosine A3 receptors | ADORA3, ADORA2A, ADORA1 | MYC 4788/4885WDR5 3585/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.